Presenting a New Paradigm for Drug Discovery: Combining Computational Biophysics and AI through MatchMaker

In this Special Perspective, our fourth in an ongoing series, we will be presenting MatchMaker™, a novel deep proteome screening technology that we have developed and validated over the past 2 years to identify DTIs. MatchMaker builds on Cyclica’s passions of combining protein, chemistry, and genomic data, and augmenting it with high performance computing and algorithm development supported on the cloud.

The Pharmaceutical Industry is Changing.

Fast, accurate, and generalizable drug-target interaction (DTI) predictions have the potential to transform pharmaceutical R&D. In this Special Perspective, our fourth in an ongoing series, we will be presenting MatchMaker™, a novel deep proteome screening technology that we have developed and validated over the past 2 years to identify DTIs. MatchMaker builds on Cyclica’s passions of combining protein, chemistry, and genomic data, and augmenting it with high performance computing and algorithm development supported on the cloud.

MatchMaker combines molecular biophysics and deep learning to predict binding of new drug molecules to all proteins, i.e. the “cell”, with high accuracy and high throughput, moving beyond the reliance on molecular docking. MatchMaker will be the engine that powers our Ligand Express proteome screening platform, and our yet to be released Differential Drug Design (DDD) technology for lead optimization as well as single and multi-target target drug design. MatchMaker will increase the speed, predictive power, and generalizability of these technologies, enabling an integrated in silico first workflow and turning our attention to designing drugs for patients, not just one protein. Prior to releasing this Special Perspective and the accompanying validation notes, we shared the story with a number of partners and investors during the annual JP Morgan Healthcare Conference between January, 7-9, 2019. The response was energizing. We are therefore thrilled to share with you MatchMaker, but before diving into details, let’s take a quick step back.

Cyclica combines knowledge about proteins, drug design, ‘-omics’ big data, and artificial intelligence to bring a revolutionary platform to the market.